Biovac's R2bn plan for vaccine production and export

25 July 2021 - 05:15 By HILARY JOFFE

The Cape Town company that has signed with Pfizer and BioNTech to produce their Covid vaccine for distribution in Africa is planning a new €130m (about R2bn) facility that could produce up to 500-million doses a year by 2026, and is in talks with development finance institutions (DFIs) to fund this.

The Biovac Institute, which was SA's only vaccine manufacturer until Aspen entered the market with the Johnson & Johnson (J&J) Covid vaccine earlier this year, is to start producing the Pfizer-BioNTech vaccine by the end of this year, ramping up to 100-million doses a year in terms of its agreement with the two companies...

This article is reserved for Sunday Times subscribers.

A subscription gives you full digital access to all Sunday Times content.

Already subscribed? Simply sign in below.

Registered on the BusinessLIVE, Business Day or Financial Mail websites? Sign in with the same details.



Questions or problems? Email helpdesk@timeslive.co.za or call 0860 52 52 00.